Prof Prof Aleix Prat speaks to ecancer about his talk at BGICC 2023 on HER2DX: a new diagnostic tool for early-stage HER2 positive breast cancer.
He explains that HER2DX is a new assay that is the result of 10 years of research in early-stage HER2 positive breast cancer.
Prof Prat then outlines the three types of information that HER2DX can provide for oncologists.